Acidification of the Golgi apparatus is indispensable for maturation but not for cell surface delivery of Ret.
We examined the effect of concanamycin A and bafilomycin A1, inhibitors of the vacuolar proton-ATPase, on maturation and expression of Ret, a tyrosine kinase receptor for glial cell line-derived neurotrophic factor. Ret appeared as 150- and 170-kDa bands on sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and both forms were sensitive to peptide-N-glycosidase F. Western and immunocytochemical analyses revealed that the 150-kDa immature form of Ret accumulated in the Golgi apparatus upon treatment with vacuolar proton-ATPase inhibitors, whereas, the 170-kDa mature form of Ret was dramatically decreased. The result suggests that glycosylation of Ret during the conversion from immature forms to mature forms is pH sensitive, and is likely initiated in the acidic trans-Golgi apparatus. In contrast, glycosylation of nascent receptors to become immature receptors appeared to be pH insensitive, and are likely to take place in the endoplasmic reticulum. The immature form of Ret was present in the plasma membrane when the cells were treated with the vacuolar proton-ATPase inhibitors. In conclusion, the acidification of the Golgi apparatus is crucial for maturation of Ret but not indispensable for trafficking of receptors to the membrane.
Hirata
Yoko
Y
Department of Biomolecular Science, Faculty of Engineering, Gifu University, Yanagido, Gifu, Japan. yokoh@gifu-u.ac.jp
Shimokawa
Norihiro
N
Oh-hashi
Kentaro
K
Yu
Zu-Xi
ZX
Kiuchi
Kazutoshi
K
D000818:Animals; D019921:Biotinylation; D015153:Blotting, Western; D002462:Cell Membrane / Q000378:metabolism; D004591:Electrophoresis, Polyacrylamide Gel; D004791:Enzyme Inhibitors / Q000494:pharmacology; D066246:ErbB Receptors / Q000378:metabolism; D006056:Golgi Apparatus / Q000502:physiology*; D007150:Immunohistochemistry; D018942:Macrolides / Q000494:pharmacology; D016716:PC12 Cells; D051096:Proto-Oncogene Proteins c-ret / Q000378:metabolism*; D051381:Rats; D020917:Receptor, trkA / Q000096:biosynthesis / Q000235:genetics; D011956:Receptors, Cell Surface / Q000378:metabolism*
D004791:Enzyme Inhibitors; D018942:Macrolides; D011956:Receptors, Cell Surface; C036978:concanamycin A; C040929:bafilomycin A1; D066246:ErbB Receptors; D051096:Proto-Oncogene Proteins c-ret; D020917:Receptor, trkA
Cell Growth Differ. 1994 Mar;5(3):305-11
8018563
J Biol Chem. 1984 Oct 25;259(20):12586-94
6092339
Oncogene. 1993 Nov;8(11):2925-9
8414495
J Neurochem. 2007 Sep;102(5):1606-1613
17555550
J Biol Chem. 1998 Jan 23;273(4):2044-51
9442042
Cell. 1985 Sep;42(2):581-8
2992805
J Exp Biol. 2009 Jun;212(Pt 11):1604-10
19448070
Nat Rev Neurosci. 2002 May;3(5):383-94
11988777
Adv Drug Deliv Rev. 2003 Nov 14;55(11):1405-19
14597138
J Cell Biol. 1997 Nov 17;139(4):929-40
9362511
Nature. 1994 Jan 27;367(6461):375-6
7906866
J Exp Biol. 1997 Jan;200(Pt 1):1-8
9023991
Nature. 1994 Jan 27;367(6461):377-8
8114938
J Biol Chem. 1995 Mar 10;270(10):4967-70
7890600
J Neurochem. 2007 Mar;100(5):1169-76
17241133
Cancer Lett. 2004 Feb 20;204(2):197-211
15013219
J Membr Biol. 2001 Aug 1;182(3):159-69
11547339
J Cell Biol. 1992 Mar;116(5):1071-80
1740466
Nature. 1994 Jan 27;367(6461):378-80
8114939
J Biochem. 1988 Sep;104(3):388-96
3149275
Trends Biochem Sci. 1989 Mar;14(3):113-6
2524915
Curr Opin Cell Biol. 2008 Aug;20(4):415-26
18511251
J Biochem. 2002 May;131(5):647-51
11983070
Development. 1993 Dec;119(4):1005-17
8306871
J Biol Chem. 1986 Nov 15;261(32):15233-41
3490480
Oncogene. 1991 Feb;6(2):297-301
2000222
Biochim Biophys Acta. 1985 Dec 19;821(3):393-403
2934093
Cell. 1999 Apr 16;97(2):153-5
10219235
Eur J Biochem. 2000 Sep;267(17):5646-54
10951226
Int Rev Cytol. 2003;226:259-319
12921239